{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:29:00Z","timestamp":1790836140800,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40265-020-01275-2","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T12:03:04Z","timestamp":1582632184000},"page":"433-439","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Avapritinib: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"issue":"1","key":"1275_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17(1):58.","journal-title":"Mol Cancer."},{"key":"1275_CR2","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: soft tissue sarcoma (version 4.2019). 2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma.pdf. Accessed 22 Jan 2020."},{"issue":"414","key":"1275_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aao1690","volume":"9","author":"EK Evans","year":"2017","unstructured":"Evans EK, Gardino AK, Kim JL, et al. A precision therapy against cancers driven by KIT\/PDGFRA mutations. Sci Transl Med. 2017;9(414):1\u201311.","journal-title":"Sci Transl Med."},{"issue":"2","key":"1275_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1158\/1078-0432.CCR-18-1858","volume":"25","author":"YK Gebreyohannes","year":"2019","unstructured":"Gebreyohannes YK, Wozniak A, Zhai ME, et al. Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors. Clin Cancer Res. 2019;25(2):609\u201318.","journal-title":"Clin Cancer Res."},{"key":"1275_CR5","unstructured":"Blueprint Medicines Corporation. AYVAKIT (avapritinib): US prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212608s000lbl.pdf. Accessed 17 Jan 2020."},{"key":"1275_CR6","unstructured":"US Food & Drug Administration. FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation [media release]. 2020. https:\/\/www.fda.gov."},{"key":"1275_CR7","unstructured":"Blueprint Medicines. Blueprint Medicines announces FDA approval of AYVAKIT\u2122 (avapritinib) for the treatment of adults with unresectable or metastatic PDGFRA Exon 18 mutant gastrointestinal stromal tumor [media release]. 2020. http:\/\/ir.blueprintmedicines.com\/."},{"key":"1275_CR8","unstructured":"United States Securities And Exchange Commission. Form 8-K. 2020. http:\/\/ir.blueprintmedicines.com\/static-files\/760ac82a-c1ad-4d52-bcba-b3bd3bdb6310. Accessed 10 Feb 2020."},{"key":"1275_CR9","unstructured":"Blueprint Medicines Corporation, CStone Pharmaceuticals. Blueprint Medicines and CStone Pharmaceuticals announce exclusive collaboration and license agreement to develop and commercialize avapritinib, BLU-554 and BLU-667 in Greater China [media release]. 2018. http:\/\/ir.blueprintmedicines.com."},{"issue":"4","key":"1275_CR10","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/bjh.16092","volume":"187","author":"E Weisberg","year":"2019","unstructured":"Weisberg E, Meng C, Case AE, et al. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. Br J Haematol. 2019;187(4):488\u2013501.","journal-title":"Br J Haematol."},{"issue":"7","key":"1275_CR11","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1021\/acs.molpharmaceut.9b00274","volume":"16","author":"CP Wu","year":"2019","unstructured":"Wu CP, Lusvarghi S, Wang JC, et al. Avapritinib: a selective inhibitor of KIT and PDGFRalpha that reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cell lines. Mol Pharm. 2019;16(7):3040\u201352.","journal-title":"Mol Pharm."},{"issue":"16","key":"1275_CR12","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1158\/0008-5472.CAN-18-3139","volume":"79","author":"B Apsel Winger","year":"2019","unstructured":"Apsel Winger B, Cortopassi WA, Garrido Ruiz D, et al. ATP-competitive inhibitors midostaurin and avapritinib have distinct resistance profiles in exon 17-mutant KIT. Cancer Res. 2019;79(16):4283\u201392.","journal-title":"Cancer Res."},{"key":"1275_CR13","doi-asserted-by":"crossref","unstructured":"George S, Bauer S, Jones RL, et al. Correlation of ctDNA and response in patients (pts) with PDGFRa D842 GIST treated with avapritinib (abstract no. 1623P and poster). Ann Oncol. 2018;29 (Suppl 8):viii584.","DOI":"10.1093\/annonc\/mdy299.021"},{"key":"1275_CR14","doi-asserted-by":"crossref","unstructured":"Heinrich M, Jones R, Von Mehren M, et al. Clinical response to avapritinib by RECIST and Choi Criteria in \u22654th Line and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST) (oral presentation). In: Connective Tissue Oncology Society annual meeting. 2019.","DOI":"10.1200\/JCO.2019.37.15_suppl.11022"},{"key":"1275_CR15","doi-asserted-by":"crossref","unstructured":"Heinrich MC, Jones RL, Von Mehren M, et al. Clinical activity of avapritinib in > fourth-line (4L+) and PDGFRA exon 18 gastrointestinal stromal tumors (GIST) (abstract no. 11022 and poster). J Clin Oncol Conf. 2019;37(Suppl 15).","DOI":"10.1200\/JCO.2019.37.15_suppl.11022"},{"key":"1275_CR16","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/01.HS9.0000561600.89121.38","volume":"3","author":"D. Radia","year":"2019","unstructured":"Radia D, Deininger MW, Gotlib J, et al. Avapritinib, a potent and selective inhibitor of Kit D816V, induces complete and durable responses in patients (pts) with advanced systemic mastocytosis (AdvSM) (abstract no. S830 and oral presentation). HemaSphere. 2019;3(Suppl 1).","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"1275_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1182\/blood-2018-99-112017","volume":"132","author":"Jason R. Gotlib","year":"2018","unstructured":"Gotlib JR, Radia D, DeAngelo DJ, et al. Avapritinib, a potent and selective inhibitor of KIT D816V, improves symptoms of advanced systemic mastocytosis (AdvSM): analyses of patient reported outcomes (PROs) from the phase 1 (EXPLORER) study using the (AdvSM) symptom assessment form (AdvSM-SAF), a new PRO questionnaire for (AdvSM) (abstract no. 351 and oral presentation). Blood. 2018;132(Suppl 1).","journal-title":"Blood"},{"issue":"Supplement_1","key":"1275_CR18","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1182\/blood-2019-126035","volume":"134","author":"Cem Akin","year":"2019","unstructured":"Akin C, Sabato V, Gotlib J, et al. PIONEER: A randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent or smoldering systemic mastocytosis with symptoms inadequately controlled with standard therapy (abstract no. 2950 and poster). Blood. 2019;134(Suppl 1).","journal-title":"Blood"},{"key":"1275_CR19","unstructured":"Joseph CP, Abaricia SN, Angellis MA, et al. Avapritinib for the treatment of GIST: analysis of efficiency, safety, and patient management strategies at the recommended phase 2 dose (abstract no. 3258000 and poster). In: Connective Tissue Oncology Society annual meeting. 2019."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01275-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-020-01275-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01275-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T22:24:04Z","timestamp":1614551044000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-020-01275-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1275"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01275-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,25]]},"assertion":[{"value":"25 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. S. Dhillon, a contracted employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}